SLDB Solid Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLDB

Price (delayed)

$7.26

Market cap

$714.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.95

Enterprise value

$437.67M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by ...

Highlights
SLDB's quick ratio has surged by 123% since the previous quarter and by 18% year-on-year
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The net income fell by 37% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://solidbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of SLDB

SLDB stock price

How has the Solid Biosciences stock price performed over time
Intraday
5.99%
1 week
2.69%
1 month
0.41%
1 year
89.06%
YTD
28.72%
QTD
0.83%

Financial performance

How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$196.46M
Net income
-$191.78M
Gross margin
N/A
Net margin
N/A
The net income fell by 37% YoY and by 10% QoQ
The operating income has declined by 37% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does SLDB's price correlate with its fundamentals

Growth

What is Solid Biosciences's growth rate over time

Valuation

What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 35% year-on-year and by 2% since the previous quarter
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The price to book (P/B) is 50% more than the 5-year quarterly average of 1.2 but 10% less than the last 4 quarters average of 2.0

Efficiency

How efficient is Solid Biosciences business performance
The ROIC is down by 14% YoY and by 12% QoQ
The return on assets has declined by 8% year-on-year and by 3% since the previous quarter
Solid Biosciences's return on equity has decreased by 6% YoY

Dividends

What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLDB.

Financial health

How did Solid Biosciences financials performed over time
SLDB's quick ratio has surged by 123% since the previous quarter and by 18% year-on-year
Solid Biosciences's current ratio has surged by 113% QoQ and by 20% YoY
The debt is 94% lower than the equity
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The debt to equity has plunged by 50% from the previous quarter and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.